Gastrointestinal stromal tumors (GISTs): Focus on histopathological diagnosis and biomolecular features

Annals of Oncology

Volumn 18, Issue SUPPL. 6, 2007, Pages

  Badalamenti, G ^a   Rodolico, V ^a   Fulfaro, F ^a   Cascio, S ^a   Cipolla, C ^a   Cicero, G ^a   Incorvaia, L ^a   Sanfilippo, M ^a   Intrivici, C ^a   Sandonato, L ^a   Pantuso, G ^a   Latteri, M A ^a   Gebbia, N ^a   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Gastrointestinal stromal tumors; Histopathological diagnosis; Molecular biology; Novel therapies

Indexed keywords

GROWTH FACTOR RECEPTOR; IMATINIB; ISOPROTEIN; MEMBRANE RECEPTOR; PLACEBO; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR; SUNITINIB;

ANTINEOPLASTIC ACTIVITY; CANCER GENETICS; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CELL TRANSFORMATION; CHROMOSOME 4; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DIGESTIVE SYSTEM CANCER; DISEASE ACTIVITY; DISEASE COURSE; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE FREQUENCY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTERSTITIAL CELL OF CAJAL; LEIOMYOMA; LEIOMYOSARCOMA; MITOSIS; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; RADIOFREQUENCY ABLATION; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR LOCALIZATION; TUMOR VOLUME; CHEMISTRY; DRUG RESISTANCE; GENETICS; PATHOLOGY; REVIEW;

DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS;

EID: 35648940832     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm243     Document Type: Conference Paper

References (29)

1. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33: 459-465.
2. Ranchod M, Kempson RL. Smooth muscle tumors of the gastrointestinal tract and retroperitoneum: A pathologic analysis of 100 cases. Cancer 1977; 39: 255-262.
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130(10): 1466-1478.
4. Corless CL, McGreevey L, Haley A et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160:1567-1572.
5. Rubin BP, Singer S, Tsao C et al. KIT activation is an ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-8121.
6. Consensus meeting for the management of gastrointestinal stromall tumours. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005; 16: 566-578.
7. Landi B, Bouche O, Blay JY. Gastrointestinal stromal tumors (GIST). Gastroenterol Clin Biol 2006; 2: 2S98-2S101.
8. Mazur MT, Clark HB. Gastric stromal tumours. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-519.
9. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumour (GIPACT): Gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152:1259-1269.
10. Sakurai S, Fukasawa T, Chong JM et al. Embryonic form of smooth muscle myosin heavy chain (SMemb/MHC-B) in gastrointestinal stromal tumour and interstitial cells of Cajal. Am J Pathol 1999; 154: 23-28.
11. Nishida T, Hirota S. Biological and clinical review of stromal tumours in the gastrointestinal tract. Histol Histopathol 2000; 15: 1293-1301.
12. Chan J. Mesenchymal tumours of the gastrointestinal tract: A paradise for acronyms (STUMP, GIST, GANT, and now GIPACT), Implication of c-kit in genesis, and yet another of the many emerging roles of the interstitial cell of Cajal in the pathogenesis of gastrointestinal diseases? Adv Anat Pathol 1999; 6: 19-40.
13. Miettinen M, Monihan A Sarlomo-Rikala M et al. Gastrointestinal stromal tumours/smooth muscle tumours (GISTs) primary in the omentum and mesentery: Clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999; 23: 1109-1118.
14. Wang L, Vargas H, French SW. Cellular origin of gastrointestrial stromal tumours: A shidy of 27 cases. Arch Pathol Lab Med 2000; 124: 1471-1475.
15. De Silva CM, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib. Pathol Oncol Res 2003; 9: 13-19.
16. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
17. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. C0117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998; 11: 728-734.
18. Heinrich M, Rubin B, Longley B, Fletcher J. Biology and genetic aspects of gastrointestinal stromal tumours: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 484-495.
19. Heinrich M, Corless C, Demetri G et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour. J Clin Oncol 2003; 21: 4342-4349.
20. Corless CL, Schroeder A, Griffith D et al. PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23(23): 5357-5364.
21. Daum O, Grossmann P, Vanecek T et al. Diagnostic morphological features of PDGFRA-mutated gastrointestinal stromal tumors: Molecular genetic and histologic analysis of 60 Gases of gastric gastrointestinal stromal tumors. Ann Diagn Pathol 2007; 11(1): 27-33.
22. Tamborini E, Pricl S, Negri T et al. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene 2006; 25(45): 6140-6146.
23. Antonescu CR, Besmer P, Guo T et al. Acquired resistance to imatiniti in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11(11): 4182-4190.
24. Chen LL, Trent JC, Wu EF et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64(17): 5913-5919.
25. Tamborini E, Bonadiman L, Greco A et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127(1): 294-299.
26. Roberts KG, Odell AF, Byrnes EM et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 2007; 6(3): 1159-1166.
27. Wardelmann E, Merkelbach-Bruse S, Pauls K et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006; 12(6): 1743-1749.
28. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368(9544): 1329-1338.
29. Goodman VL, Rock EP, Dagher R et al. Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13(5): 1367-1373.